Your session is about to expire
← Back to Search
Other
MQ710 + Pembrolizumab for Solid Tumor Cancers
Phase 1
Recruiting
Led By Lara Dunn, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 18 or over
Prior non-immunotherapy, anti-tumor treatment including endocrine, chemical/radiotherapy, targeted therapy, or major surgery (but not anti-PD1/- L1 therapies) was discontinued for more than 4 weeks prior to enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
Study Summary
This trial looks at the effects of a new drug, MQ710, on people with advanced or relapsed solid tumor cancers. It will find the best dose with fewest side effects.
Who is the study for?
This trial is for adults with advanced or metastatic solid tumor cancers that have relapsed, worsened after standard treatments, or have no standard treatment options. Eligible participants include those with specific skin cancers and head and neck squamous cell carcinoma who've failed previous therapies including anti-PD-1 therapy (except HNSCC patients with low PD-L1 expression). Participants must be in good enough health to comply with study procedures, not pregnant, willing to use contraception, and free from significant recent medical issues.Check my eligibility
What is being tested?
The study aims to determine the highest dose of MQ710 that can be given safely alongside Pembrolizumab in people with various types of solid tumors. It will involve individuals whose cancer has returned at the original site or spread elsewhere and is resistant to conventional treatments or lacks such options.See study design
What are the potential side effects?
Potential side effects are not explicitly listed but may include typical reactions associated with immunotherapy drugs like inflammation in organs, infusion-related reactions, fatigue, digestive problems, blood disorders, increased risk of infections as well as any adverse effects related to the new drug's mechanism which will be monitored closely.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I stopped any cancer treatments except for anti-PD1/-L1 more than 4 weeks ago.
Select...
I have had a biopsy to check my condition.
Select...
My advanced cancer has not responded to 2 previous treatments, or there are fewer than 2 standard treatments available.
Select...
I have no curative treatment options left or they come with high risks.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My kidney function is good with a creatinine level below 2 mg/dL.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety of MQ710 by review of AEs and SAEs
Trial Design
2Treatment groups
Experimental Treatment
Group I: Dose Expansion GroupExperimental Treatment2 Interventions
MQ710 + pembrolizumab
Approximately 8 patients will be recruited into the dose expansion group for monotherapy dosing of MQ710. Approximately 12 patients will be recruited for dosing at the MTD/maximally administered dose established in combination with pembrolizumab.
Group II: Dose Escalation GroupExperimental Treatment1 Intervention
MQ710
The dose levels will be escalated following a standard 3+3 dose escalation scheme.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 2
~2010
Find a Location
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,936 Previous Clinical Trials
588,842 Total Patients Enrolled
Lara Dunn, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
54 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a history of chronic liver disease or cirrhosis.I have a specific type of skin cancer and standard treatments haven't worked for me.I have not had an uncontrolled infection in the last 6 months.I had leukemia (ALL or CLL) or aggressive lymphoma but am in remission and not on immunosuppressive therapy.I am 18 years old or older.I have an autoimmune disease treated with medication in the last 2 years.I have skin cancer or related conditions and standard treatments haven’t worked.I do not have active viral diseases like hepatitis or HIV, nor have I taken antiviral treatments recently.I have melanoma with a BRAF mutation and have been treated with BRAF-targeted therapy.I am not pregnant and agree to use birth control during and up to 90 days after the study.I stopped any cancer treatments except for anti-PD1/-L1 more than 4 weeks ago.I have at least 2 tumors that can be injected and measured.My blood and bone marrow are functioning well.I have been hospitalized for serious bleeding in the last year.I haven't had severe bleeding or blood clot issues in the last 3 months.I haven't had cancer treatment or major surgery in the last 28 days and have mostly recovered from past treatments.You are at risk of having trouble breathing if the tumor swells after the injection.My tumor is affecting major blood vessels or organs, risking perforation.You are expected to live for at least 3 months.My liver is working well.I have had a biopsy to check my condition.I have skin cancer or head and neck cancer and it didn't respond to initial immune therapy.I do not have any ongoing infections needing antibiotics or causing frequent high fevers.I have had radiation treatment before that included my carotid arteries.My surgical wound has not fully healed.I have had anti-PD1/-PDL1 treatment before but stopped it at least 3 weeks ago.I have not had serious heart problems or strokes in the last 6 months.I have had my spleen removed.My cancer has spread to my brain or its coverings.Your oxygen levels are below 92% while breathing normal air.You are allergic to the ingredients in the MQ710 transgene products or its formulation.I need blood-thinning medication like warfarin.My advanced cancer has not responded to 2 previous treatments, or there are fewer than 2 standard treatments available.I have at least one tumor that can be measured.I have a history of lung conditions like pulmonary fibrosis or pneumonitis.I have no curative treatment options left or they come with high risks.I am fully active or restricted in physically strenuous activity but can do light work.My advanced disease has not improved with standard treatments, or there are no standard treatments for it, or I cannot undergo standard treatments due to health reasons.I am not currently taking high doses of steroids or immunosuppressants.I have not received a live vaccine in the last 28 days.I haven't had immune therapy treatments in the last 3 weeks.My kidney function is good with a creatinine level below 2 mg/dL.
Research Study Groups:
This trial has the following groups:- Group 1: Dose Escalation Group
- Group 2: Dose Expansion Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is the Dose Escalation Group a reliable option for patients seeking treatment?
"The safety of Dose Escalation Group was rated a 1 as this is an early-phase trial, thus data supporting its safety and efficacy has not been thoroughly established."
Answered by AI
Is this experiment in search of more participants?
"Affirmative. Clinicaltrials.gov hosts information affirming that this clinical trial, posted on May 4th 2023 and last updated 11 days later, is currently recruiting patients from seven sites with the aim to find 56 participants."
Answered by AI
How many facilities are currently overseeing this scientific experiment?
"Currently, this medical trial is running in 7 locations around Middletown, Montvale and Commack. To reduce the need for travel when enrolling, it's best to select a site near you."
Answered by AI
How many participants are registering for this study?
"Yes, the clinical trial is still recruiting. According to information hosted on clinicaltrials.gov, this experiment was first announced on May 4th 2023 and has since been updated at least once as of May 11th 2023. The team responsible for the study need 56 people across 7 sites in order to complete it."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger